Loss narrows on cost discipline. Black Diamond Therapeutics reported a loss of $0.27 per share for Q4 2025, narrower than the consensus estimate of a $0.17 loss. The biotech posted a narrower loss than expected by 19.9%, marking the third consecutive quarter of better-than-expected results. The company recorded a net loss of $7.8 million for the quarter.
Revenue remains absent. Black Diamond reported zero revenue for Q4 2025, falling short of the $9.4 million average analyst estimate. The pre-commercial biotech has now posted three consecutive quarters of zero revenue following Q1 2025’s $70 million in collaboration revenue. The revenue miss reflects the company’s ongoing clinical-stage status with no marketed products generating commercial sales.
Analyst support holds firm. The Street maintains a bullish stance with eight of nine analysts rating shares Buy or better, unchanged from the prior two months. Trading volume of 346,878 shares came in below recent averages as the stock held steady at $2.12. Shares trade 57% below the 52-week high of $4.94 set earlier in the fiscal year.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.